FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its fourth quarter and full year 2025 financial results prior to the open of the U.S. financial markets on Tuesday, February 17, 2026. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Rel ...

Core Insights - NeoGenomics, Inc. announced preliminary fourth quarter and full-year 2025 revenue, indicating a commitment to being the preferred cancer testing partner for pathologists and oncologists [2][6] - The company expects fourth quarter revenue of approximately $190 million, reflecting an 11% year-over-year growth, and full-year revenue of approximately $727 million, representing a 10% year-over-year growth [6] Revenue Summary - For the fourth quarter of 2025, NeoGenomics anticipates total revenue of around $190 million, which is an 11% increase compared to the previous year [6] - The projected total revenue for the full year 2025 is approximately $727 million, showing a 10% growth year-over-year [6] CFO Transition - NeoGenomics announced a succession plan for its Chief Financial Officer, with Abhishek Jain joining as Executive Vice President on January 12, 2026, and transitioning to CFO on March 2, 2026 [3][4] - Current CFO Jeff Sherman will retire on April 14, 2026, after ensuring a smooth transition [3][4] Leadership Insights - Abhishek Jain has a strong background in guiding life sciences companies through growth and transformation, and he aims to enhance financial discipline and operational efficiency at NeoGenomics [4] - Jeff Sherman expressed confidence in the company's ability to innovate in therapy selection and minimal residual disease (MRD) testing, particularly in community settings [4]